

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**国药集团**  
SINOPHARM

**CHINA TRADITIONAL CHINESE MEDICINE HOLDINGS CO. LIMITED**

**中國中藥控股有限公司**

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code: 570)**

**INSIDE INFORMATION**  
**ISSUANCE OF THE 2022 FIRST TRANCHE OF SUPER & SHORT TERM**  
**COMMERCIAL PAPER**  
**AT THE NATIONAL ASSOCIATION OF FINANCIAL MARKET**  
**INSTITUTIONAL INVESTORS**

This announcement is made by China Traditional Chinese Medicine Holdings Co. Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

On 10 January 2022, the Company received notices (the “**Notices**”) issued by the National Association of Financial Market Institutional Investors (the “**Association**”) which stated that, among other things, (i) the issuance of a Super & Short-term Commercial Paper with an aggregated amount of RMB2.8 billion and a medium term notes with an aggregated amount of RMB2.2 billion (the “**Notes**”) are duly registered at the Association; (ii) the Notes may be issued by the Company in multiple tranches within two years from the date of the Notices; and (iii) the Company shall comply with the applicable rules, regulations and requirements stipulated by the Association in respect of the issuance, including the disclosure requirements and the intended use of the proceeds from the issuance.

The board of directors of the Company is pleased to announce that on 18 February 2022, the Company has completed the issuance of the 2022 first tranche of Super & Short-term Commercial Paper (the “**Issue**”), for an aggregate amount of RMB1 billion, with a maturity of 270 days and coupon rate of 2.40% per annum. The proceeds from the Issue is intended to be used for the repayment of RMB1 billion Super & Short-term Commercial Paper which will be matured in 25 February 2022.

A memorandum containing information of the Issue will be disclosed on the website of China Money (<http://www.chinamoney.com.cn/>) and Shanghai Clearing House (<http://www.shclearing.com/>).

By Order of the Board  
**China Traditional Chinese Medicine Holdings Co. Limited**  
**WU Xian**  
*Chairman*

Hong Kong, 18 February 2022

*As at the date of this announcement, the board comprises twelve directors, of which Mr. WU Xian and Mr. YANG Wenming are executive directors; Mr. WANG Xiaochun, Mr. YANG Shanhua, Ms. LI Ru, Mr. YANG Binghua, Mr. WANG Kan and Mr. KUI Kaipin are non-executive directors; and Mr. XIE Rong, Mr. YU Tze Shan Hailson, Mr. QIN Ling and Mr. LI Weidong are independent non-executive directors.*